StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.

CANF has been the topic of several other research reports. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday.

Can-Fite BioPharma Stock Performance

Shares of NYSE:CANF opened at $1.63 on Thursday. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The company has a market cap of $5.75 million, a P/E ratio of -0.91 and a beta of 1.32. The stock’s 50-day moving average is $1.88 and its 200-day moving average is $2.36.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC lifted its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.